Veterinary Clinical Reference

Look up any drug or condition.

Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.

107 evergreen hubsCited at every claimContinuously updatedFree for verified vets
Dogs & CatsJul 7, 2026

Ondansetron in Dogs and Cats: A Clinical Reference for Vomiting and Nausea

A practicing-clinician reference on ondansetron for dogs and cats: mechanism, indications, oral and IV dosing, the low-oral-bioavailability problem, how it compares with maropitant and metoclopramide, adverse effects, and the efficacy evidence.

Read →
CanineJun 19, 2026

Omeprazole and Gastroprotectants in Dogs: ACVIM Consensus, Overprescription Evidence, and Drug Interactions

Evidence-based review for DVMs: the 2018 ACVIM consensus reshaped omeprazole prescribing, yet a 265-vet survey shows persistent overprescription; long-term use raises gastrin without cobalamin change, and the feline clopidogrel interaction is PK-real but PD-limited.

Read →
Dogs & CatsJun 6, 2026

Maropitant (Cerenia) for Vomiting in Dogs and Cats: Clinical Evidence

Evidence-based review of maropitant (Cerenia) for vomiting in dogs and cats — canine motion sickness, feline CKD, dexmedetomidine-induced emesis comparators, and the emerging visceral-analgesia role — with NK1 mechanism and FDA label facts.

Read →
CanineJun 6, 2026

Capromorelin (Entyce & Elura) for Appetite Stimulation: Evidence and Clinical Use in Dogs and Cats

The clinician's evidence hub for capromorelin — the first ghrelin (GHS-R1a) receptor agonist appetite stimulant. Covers Entyce dosing and canine field-study efficacy, the Elura feline CKD pivotal RCT (+6.81% body-weight treatment effect), comparators, adverse effects, and cardiac/glycemic precautions.

Read →
FelineJun 6, 2026

Mirtazapine Transdermal Ointment (Mirataz) for Feline Weight Loss

FDA-approved mirtazapine transdermal ointment (Mirataz) for feline weight loss: pivotal field-study results, receptor mechanism, and lymphoma, CKD, and owner-adherence evidence. Includes dosing, the MAOI contraindication, and comparator guidance.

Read →